A Diagnostics Industry Roundtable: Where is Growth?
Executive SummaryAn unprecedented wave of consolidations has everyone in diagnostics pondering what's next. Four top industry executives discuss the future of consolidation, the need for broader product lines to attract large-volume buyers, and the need to eliminate excess capacity from the system. New product opportunities exist, but the high cost of R&D will likely force more collaborations, particularly with medical device and drug companies.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.